evinacumab
evinacumab: developed by 1 company · 2 clinical trials tracked.
evinacumab evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could evinacumab → RARE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) Homozygous Familial Hypercholesterolemia (HoFH) | Approved |
Clinical Trials (2)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease
Primary endpoint: Percent change in Urine Albumin to Creatinine Ratio (UACR)
Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia in a Real Life Setting in Canada
Primary endpoint: Change in lipid profile
Frequently asked questions
Who is developing evinacumab?
evinacumab is being developed by Ultragenyx Pharmaceutical Inc..
How many clinical trials involve evinacumab?
BioSniper tracks 2 clinical trials involving evinacumab.